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The polymorphic deletion of Glu-155 from human glutathi-
one transferase omega1 (GSTO1-1) occurs in most popula-
tions. Although the recombinant Glu-155 enzyme expressed
in Escherichia coli is active, the deletion causes a deficiency of
the active enzyme in vivo. The crystal structure and the fold-
ing/unfolding kinetics of the Glu-155 variant were deter-
mined in order to investigate the cause of the rapid loss of the
enzyme in human cells. The crystal structure revealed altered
packing around the Glu-155 deletion, an increase in the pre-
dicted solvent-accessible area and a corresponding reduction
in the buried surface area. This increase in solvent accessibility
was consistent with an elevated Stern-Volmer constant. The
unfolding of both the wild type and Glu-155 enzyme in urea
is best described by a three-state model, and there is evidence
for the more pronounced population of an intermediate state
by the Glu-155 enzymes. Studies using intrinsic fluorescence
revealed a free energy change around 14.4 kcal/mol for
the wild type compared with around 8.6 kcal/mol for the
Glu-155 variant, which indicates a decrease in stability asso-
ciated with the Glu-155 deletion. Urea induced unfolding of
the wild type GSTO1-1 was reversible through an initial fast
phase followed by a second slow phase. In contrast, the Glu-
155 variant lacks the slow phase, indicating a refolding defect.
It is possible that in some conditions in vivo, the increased
solvent-accessible area and the low stability of the Glu-155
variant may promote its unfolding, whereas the refolding de-
fect limits its refolding, resulting in GSTO1-1 deficiency.
The omega class glutathione transferases (GSTO)2 are
among the more recently identified members of the cytosolic
glutathione transferase super family (1, 2). Members of the
omega class have a number of novel features and have been
implicated in important metabolic pathways and in the etiol-
ogy of some common neurological diseases (3–7). In contrast
to the other human GSTs, which have active site tyrosine or
serine residues, the omega class GSTs have an active site cys-
teine residue that is essential for its primary catalytic activities
(1). The omega class GSTs were originally shown to catalyze
thioltransferase and ascorbate reductase reactions, and other
studies have shown that they also catalyze the reduction of
monomethyl arsonate in the methylation pathway for the dis-
position of arsenic (3, 4). In addition, recent studies have
shown that GSTO1-1 has S-phenacyl glutathione reductase
activity and plays a significant role in the biotransformation of
-haloketones (8, 9). As well as these catalytic activities,
GSTO1-1 has been implicated in the post-translational proc-
essing and activation of the proinflammatory mediator inter-
leukin-1 (10) and has also been found to act as an inhibitor
of cardiac muscle ryanodine receptor Ca2 channels (11). In-
terestingly, some genetic mapping studies have strongly im-
plicated an omega class GST as a factor influencing the age at
onset of Alzheimer and Parkinson diseases (5, 6, 12). Other
studies have implicated genetic variation in GSTO1 in vascu-
lar dementia, stroke, and cerebrovascular atherosclerosis (7,
13). The mechanism by which genetic variation mediates
these effects has not been determined, but it could be via the
effects on the activity or expression of the omega class GSTs.
Previous studies have identified a range of polymorphisms
in the GSTO genes (2, 3, 14). Although a number of single
nucleotide polymorphisms have been identified in non-coding
regions, their effects on transcription, splicing, and mRNA
stability have yet to be evaluated (15). In contrast, several
polymorphisms in coding regions have been studied in more
detail (2, 3, 14, 16). A polymorphic deletion of three base pairs
at the junction of exon 4 and intron 4 is of particular interest.
This deletion could result in the deletion of Glu-155 or a
splicing abnormality. This polymorphism has been identified
in a range of different ethnic groups reaching a frequency of
10% in one Chinese sample (2, 14, 17–19). The deletion oc-
curs in two haplotypes characterized by a Glu or Lys at posi-
tion 208 (19). Recombinant expression of the Glu-155 dele-
tion variant in Escherichia coli affords an active enzyme that
has decreased heat stability (2, 19). We recently reported that
the T-47D breast cancer cell line is hemizygous for the Glu-
155 deletion allele and is deficient in GSTO1-1 enzymatic
activity (20). In addition, lymphoblastoid cell lines from indi-
viduals who were heterozygous for the Glu-155 deletion were
reported to have only 50% of normal catalytic activity with
4-nitrophenacylglutathione, a specific GSTO1-1 substrate
(20). These studies suggest that the Glu-155 deletion variant
is very compromised in vivo.
Given the role played by GSTO1-1 in the disposition of
-haloketones (8) and the targeting of GSTO1-1 by anti-in-
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flammatory drugs (10) as well as the proposed role of genetic
variation in GSTO1 in the progress of several neurological
disorders (6, 7), it is apparent that natural polymorphisms in
GSTO1 that affect function are of significant pharmacoge-
netic and clinical interest. Consequently we have investigated
the effect of the polymorphic Glu-155 deletion on the enzyme
structure and stability by solving its crystal structure and
studying its unfolding equilibrium.
EXPERIMENTAL PROCEDURES
Expression of Recombinant GSTO1-1 Variants—In this
study several recombinant GSTO1-1 isoenzymes have been
studied. There is a common polymorphism where Asp-140
substitutes Ala-140. This substitution does not appear to in-
fluence function, but because Ala-140 is the most common
allele, we refer to it as the wild type and the substituted vari-
ant as A140D. In each case the Glu-155 deletion variants have
alanine at residue 140. cDNAs encoding GSTO1 wild type,
GSTO1-A140D, GSTO1 Glu-155/Glu-208, and GSTO1
Glu-155/Lys-208 were cloned into the pHUE expression
vector and transfected into E. coli BL21(DE3). The expression
and purification of recombinant proteins using the pHUE
vector and ubiquitin cleavage techniques have been previously
described in detail (21). Briefly, the recombinant His6-ubiq-
uitin-GSTO fusion protein was purified by chromatography
on nickel-agarose. The His-ubiquitin fusion moiety was re-
moved by digestion with the catalytic core of Usp2 and re-
chromatography on nickel-agarose. The purified proteins
were dialyzed against 20 mM Tris, pH 8, 60 mM NaCl, 5 mM
dithiothreitol for storage and crystallization experiments.
Crystallization and Structural Determination of GSTO1-1
Glu-155/Glu-208—Unsuccessful attempts were made to
grow crystals of GSTO1 Glu-155 under identical conditions
to those reported for the native enzyme (1). The protein was,
therefore, subjected to the index screen (Hampton Research)
to find new conditions. The vapor diffusion technique was
employed using a 96-well sitting drop crystallization tray
(Nunc, Roskilde, Denmark). For screening, 1 l of protein (12
mg/ml) was mixed with 1 l of 10 mM glutathione and 1 l of
reservoir solution. Reservoirs contained 100 l of each screen
condition. The tray was then sealed with Crystal Clear tape
(Hampton Research) and allowed to equilibrate at 18 °C. After
6 days, crystals were observed in condition 62 (0.1 M Tris, pH
8.5, 0.2 M trimethyl amine N-oxide dihydrate, 20% (w/v) poly-
ethylene glycol monomethyl ether 2000). Scaling up was
achieved via a doubling of the overall crystallization volume
using the same method. Crystals were flash-frozen at 100 K
using an Oxford cryostream. Cryoprotection was by sequen-
tial transfer to artificial mother liquor containing 20% glycerol
by 5% increments. The crystals were then transferred to liquid
nitrogen and stored until subsequent data collection using a
Rigaku RU-200 rotating anode x-ray generator with mirror
optics and Mar345 desktop beamline. Processing of data col-
lected from a single crystal was performed using the programs
DENZO and SCALEPACK (22). Phase information was ob-
tained by molecular replacement using the structure of the
native enzyme (1) as a search model with the program
MOLREP (23). Model rebuilding to match experimental den-
sity, including the deletion of Glu-155, was achieved with the
programs O (24) and Coot (25) and alternated with restrained
refinement by the program REFMAC (26). The program
PHENIX (27) was then employed for the final stages of refine-
ment using the simulated annealing option with default set-
tings. Finally, the programMolProbity (28) was used to add
hydrogens to the structure and diagnose Asn/Gln/His flips
before validation deposition (PDB code 3LFL).
Spectroscopy and Activity Measurements—All fluorescence
data were measured on PerkinElmer Life Sciences LS 50B lu-
minescence spectrophotometer. Tryptophan fluorescence was
used to monitor structural change. Excitation was at 295 nm,
and fluorescence was recorded in the range of 305–430 nm.
1-Anilino-8-naphthalenesulfonate (ANS) was added to pro-
tein samples in a molar ratio of 50:1 (29) and equilibrated for
50 min for complete interaction. ANS binding spectra were
recorded in the range of 405–540 nm with excitation at 390
nm. Enzymatic activity was determined with the GSTO1-1
specific substrate S-(4-nitrophenacyl)-glutathione as de-
scribed previously (9).
Tryptophan Fluorescence Quenching by Acrylamide—Acryl-
amide (8 M) was added to 1 M GSTO1 proteins (calculated
by a molar extinction coefficient of 82,800 M1cm1 at 280
nm) to achieve different concentrations and mixed thor-
oughly. Fluorescence intensities were monitored at 336 nm.
Each protein sample was repeated at least three times and
then averaged. Quenching data were analyzed by the Stern-
Volmer equation (30),
Fo
F
 1  Ksv[Q] (Eq. 1)
where Fo and F are the fluorescence intensities before and
after the addition of acrylamide, [Q] is the acrylamide concen-
tration, and KSV is the Stern-Volmer constant, which can re-
flect the burial of tryptophan residues and, thus, indicate the
protein accessibility.
Circular Dichroism Measurement—Circular dichroism
(CD) was monitored on ChirascanTM Circular Dichroism
Spectrometer (Applied Photophysics) using a cuvette with a
0.1-cm light path. Ellipticity at 222 nm was collected and plot-
ted against variation of urea concentration.
Equilibrium Unfolding Experiments—Urea-induced unfold-
ing experiments were performed in 20 mM sodium dihydro-
gen phosphate with 40 mM ammonium phosphate, pH 7.0, at
1 M protein concentration. To reach equilibrium, protein
samples with different urea concentrations (0–9 M) were in-
cubated at 30 °C for 5 h and then cooled down to room tem-
perature for intrinsic fluorescence, ANS binding, and circular
dichroism measurements. For the analysis of the intrinsic
fluorescence the ratio of emission intensity at 333 nm (folded
protein) and 355 nm (unfolded protein) was determined, and
the relative intensity at 475 nm was determined for ANS
binding. Data from three-four separate replicates from two
purification batches of each protein were averaged.
Urea unfolding curves were fitted to a two-state (N27 2U)
unfolding model or a three-state model (N27 I27 2U) (31,
32) using SigmaPlot Version 10.0. The equilibrium fractions
Structure of GSTO1-1 Glu-155
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of native, intermediate, and denatured state were calculated
by a previously described method (32).
Protein Refolding—Refolding of unfolded proteins was de-
tected using S-(4-nitrophenacyl)-glutathione reduction assay
and tryptophan fluorescence recovery. For activity reversibil-
ity, proteins were brought to a concentration of 1 M in 6 M
urea and allowed to unfold for 5 h at 30 °C. The proteins were
then diluted 6 times and allowed to refold at room tempera-
ture. Enzyme activity was determined after 1 h. When refold-
ing was monitored by intrinsic fluorescence, 30 M proteins
were fully unfolded in 7.4 M urea. The enzymes were then di-
luted 10 times, and the emission intensities were recorded
every minute. Curve fitting was undertaken in SigmaPlot Ver-
sion 10.0.
RESULTS
Crystal Structure of GSTO1 Glu-155/Lys-208—To deter-
mine whether the deletion of Glu-155 caused any significant
structural alterations, we crystallized and solved the structure
of the GSTO1 Glu-155/Glu-208 variant. The crystals were
found to be of a different space group (P21212) compared with
the native enzyme (P3121) and diffracted to 2.1 Å. Table 1
summarizes the crystallographic data and model statistics.
FIGURE 1. Structural changes induced by the deletion of Glu-155. A, a
view perpendicular to the crystallographic 2-fold axis of the native structure
(translucent yellow), the Glu-155 A monomer (cyan), and the non-crystallo-
graphic 2-fold axis of the Glu-155 B and C monomers (magenta), which
produce the GSTO1-1 physiological dimer. The position of Glu-155 and GSH
is shown in stick representation. B, a closer inspection of the deletion site
within the Glu-155 A-monomer (cyan) compared with the wild type en-
zyme (yellow) is shown. Changes to the associated residue side chain con-
formations are in stick representation. The new interaction formed at the
dimer interface is also visible. The adjacent monomer is shown in magenta.
The figures were generated using PyMol.
FIGURE 2. The flexibility of helix 9 observed in the Glu-155 structure.
A, a closer view of the A monomer active site reveals several key differences
compared with the native enzyme. Of most interest is the different rotamer
adopted by Trp-222, dramatically increasing the hydrophobicity within the
conserved H-site. The Glu-155 A-monomer is shown in cyan compared
with the wild type enzyme in yellow. B, comparison of the native structure
to that of the B monomer reveals much more pronounced structural
change. Helix 9 has shifted toward the site of glutathione binding by sev-
eral angstroms, dramatically reducing the size of the H-site. The Glu-155
B-monomer is shown in magenta with the overlaid native structure in yel-
low. The figures were generated using PyMol.
TABLE 1
X-ray data collection and refinement statistics
r.m.s.d., root mean square deviation.
Space group P21212
Unit cell parameters (Å) a  73.0, b  201.9, c  53.4
Reflections measured/unique 389,373/44,498
Resolution range (Å) 36.51-2.10 (2.18-2.10)a
R-merge (%) 12.8 (37.0)a
Completeness 94.4 (80.7)a
Mean I/I 21.4 (3.5)a
R/Rfree (%) 19.91/26.05
r.m.s.d. bonds (Å) 0.008
r.m.s.d. angles 1.120°
PDB accession code 3LFL
a The highest resolution bin.
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Molecular replacement in MOLREP (23) revealed three
monomers in the asymmetric unit. Monomer A sits adjacent
to a crystallographic 2-fold axis so as to form a physiological
dimer with its crystallographic partner (A-A). Monomers B
and C form a second dimer (B-C). The overall topology is
similar to that of the wild type enzyme, except for the follow-
ing; the deletion of residue Glu-155 results in the premature
termination of helix 5 and a conformational change in the
helix 5 to 6 loop (Fig. 1A). Its subsequent removal from the
search model required significant rebuilding of the associated
residues, a process coupled with restrained refinement until
local aberrations in themFo  DFc electron density map were
removed. As shown in Fig. 1B, several perturbations in the
surrounding structure contribute to this enzyme altered phe-
notype. The hydrophobic interactions (not shown in this fig-
ure) of adjacent residues Val-156 and Leu-157 have been dis-
rupted by C translations of 5.3 and 8.0 Å, respectively. This
has caused Val-156 to be exposed to solvent. The transloca-
tion of Leu-157, on the other hand, has produced a new inter-
action with Leu-119 and, of particular interest, an interaction
with the side chain of Pro-68 from the other subunit in the
physiological dimer, effectively creating a new interaction at
dimer interface. In addition, the Thr-158 C has shifted by
6.4 Å, allowing its side chain to occupy the position previously
inhabited by that of Val-156. Such changes have contributed
to an increase in the water accessibility of Leu-157 to 100
Å2 and an increase in the buried area at the interface of twice
this magnitude. In total there are only 7 contacts 3.5 Å be-
tween residues 150–164 of 5 and residues 192–202 of
loop-7 in the Glu-155/Glu-208 enzyme, 18 fewer than in
the wild type enzyme. The altered packing has likely played a
role in the observed refolding anomaly of Glu-155 deletion
variants discussed below. The alterations in the dimer inter-
face do not appear to preclude the formation of heterodimers
between wild type and deletion-containing monomers.
The potential flexibility of the C-terminal region can be
observed in the Glu-155/Glu-208 structure. Comparison of
the active site of monomer A with the wild type enzyme re-
veals a rotation of the putative “H-site” residue, Trp-222, re-
sulting in the removal of its indole nitrogen from the binding
pocket, increasing its hydrophobic character. As shown in Fig.
2A, the entrance to the binding pocket has also been partially
occluded by the movement of Arg-183 and Tyr-229. Helix 9,
of monomer A, which forms part of the active site, has shifted
away from the GSH binding pocket (G-site), possibly to ac-
commodate movements in residues Tyr-229 and Trp-222
(Fig. 2A). Although the B and C monomers display similar
structural changes relating to the deletion site, it is the con-
formational shift of their C termini that is most remarkable.
As shown in Fig. 2B helix 9 of monomer B has moved to-
ward the G-site and rotated so that Leu-228 and Tyr-229
block the H-site entrance. There is a significant rearrange-
ment of Trp-222, which has been excluded from the H-site
and is stacked against helix 6, exposed to bulk solvent. The
net effect is to make the “H-site” smaller. Furthermore, the
last 10–14 residues forming helix 10 and its connecting loop
fail to show substantialmFo  DFc density in monomers B
and C. These significant changes do not appear to be a conse-
quence of crystal packing, as the crystal contacts in each mon-
omer are different. The different conformations seen in the
two dimers (A-A and B-C) may, therefore, reflect the confor-
mational space sampled in solution. Such helix 9 movements
may be crucial to the binding of ligands of variable size and
shape, for example monomethyl arsonate and
dehydroascorbate.
Equilibrium Unfolding/Folding of GSTO1 Glu-155/
Glu-208—Initially, to determine whether the deletion of Glu-
155 caused subtle changes to the enzyme conformation in
solution, the Stern-Volmer constant (KSV) was calculated by
quenching the natural tryptophan fluorescence using acryl-
amide. Linear Stern-Volmer plots revealed a clear difference
between the variant enzymes with the Glu-155 deletion and
the enzymes with A or D at residue 140 (Fig. 3). This differ-
ence is reflected numerically in KSV for each enzyme (5.258
(R2  0.9989) for wild type (Ala-140), 5.840
(R2  0.9982) for A140D, 6.975 (R2  0.999) for Glu-155/
Glu-208, and 7.299 (R2  0.9979) for Glu-155/Lys-208). The
data suggest that the deletion of Glu-155 increases the acces-
FIGURE 3. Tryptophan fluorescence quenching by acrylamide. The ex-
perimental values and trend lines are shown as wild type (F), A140D (E),
Glu-155/Glu-208 (), and Glu-155/Lys-208 (‚).
TABLE 2
Interface and surface area (SA) of Glu-155/Glu-208 and wild type crystal structure
All calculations come from online PISA (35) of EBI services.
Solved residues SA of dimer
Total buried area
of dimer
Total SA of
Trp residues
in dimer
Buried area of
dimer interface
Å2 Å2 Å2 Å2
GSTO1 wild type
(PDB code 1EEM)
Ser-5–Leu-241 20,961.5 3,859.9 32.48 1,885.6
Glu-155 monomer A Ser-5–Leu-240 21,639.1 3,317.3 33.74 2,116.6
Structure of GSTO1-1 Glu-155
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sibility of tryptophan residues. This is supported by calcu-
lations from the crystal structure of increased accessible
surface area of total protein and of tryptophan residues in
the Glu-155 (Table 2).
Characterization of Urea-induced Unfolding—The unfold-
ing of the GSTO1-1 enzymes in the presence of urea was ex-
amined using tryptophan fluorescence, CD, and ANS binding
(Fig. 4). The fluorescence data (Fig. 4a) for the wild type and
A140D enzymes indicate that they do not begin unfolding
before the urea concentration exceeds 3.7 M and by visual in-
spection appear to exhibit a single transition phase. In con-
trast, the equilibrium denaturation of the Glu-155 enzymes
start to show an unfolding signal below 1 M urea and clearly
have a biphasic transition profile. The difference in the un-
folding profiles between the Glu-155-containing and Glu-
155 enzymes is also evident in the CD data (Fig. 4b) where the
Glu-155 enzymes start losing their helical secondary struc-
ture content at the lowest concentrations of urea. It is also of
FIGURE 4. The equilibrium unfolding of GSTO1-1 in urea. Unfolding was monitored by tryptophan fluorescence expressed as the ratio of fluorescence at
333 nm to the fluorescence at 355 nm (a), ellipticity at 222 nm of circular dichroism (b), and relative intensity of ANS binding (c). The three state curve fits for
N27 I27 2U are shown in a and c, and the panels immediately below a and c show the residuals obtained after fitting the data to either two or three state
models. The calculated population of the native, intermediate, and unfolded states of GSTO1-1 as a function of urea concentration are plotted for wild type
and A140D in panel d (solid line for wild type and dashed line for A140D), Glu-155/Glu-208 in panel e, and Glu-155/Lys-208 in panel f. The experimental
values for each enzyme are shown as wild type (F), A140D (E), Glu-155/Glu-208 (), and Glu-155/Lys-208 (‚).
Structure of GSTO1-1 Glu-155
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interest to note that at the starting point of the unfolding
curve in Fig. 4b the Glu-155 variants have a lower helical
content than the wild type enzymes, which is consistent with
the Glu-155/Glu-208 structure. The data from the ANS
binding measurements (Fig. 4c) provide the clearest evidence
that the unfolding profiles of the Glu-155 enzymes are dif-
ferent from the Glu-155-containing enzymes. Using trypto-
phan fluorescence, protein concentration dependence was
observed for the transition phase of the wild type enzyme and
notably only during the second transition phase of the Glu-
155/Glu-208 enzyme (Fig. 5). Taken together, these data sug-
gested that the equilibrium unfolding of the wild type and
A140D enzymes might be described by a two-state model
(N27 2U), whereas the unfolding of the Glu-155 enzymes
might best be described by a three-state unfolding model
(N27 I27 2U), where I2 represents a partially unfolded di-
meric intermediate (33, 34).
Tryptophan fluorescence and ANS binding data from the
Glu-155 enzymes were fitted to a three-state model with an
R2  0.999, whereas the fitting of fluorescence data from the
wild type and A140D enzymes to a two-state model gave a
lower R2 (0.9986 and 0.9974, respectively) and lower free en-
ergy values (6.41 and 5.15 kcal/mol, respectively) that were
inconsistent with the previously observed lower thermal sta-
bility for Glu-155 enzymes (2). When the three-state model
was used to re-fit the data from the wild type and A140D en-
zymes, a better fit (Fig. 4a) with a higher R2 (0.9996 and
0.9993, respectively) was obtained. The distribution of residu-
als for a two-state and three-state fit for the wild type and
A140D enzymes is shown in Fig. 4a, and the residual sums of
squares for wild type and A140D enzymes were also improved
from 0.0037 and 0.0062 to 0.0010 and 0.0017. Based on the
fitting result, equilibrium denaturation of the wild type and
A140D proteins appears to be better described by a three-
state unfolding model. Given the absence of protein concen-
tration dependence through the first transition phase of the
Glu-155 enzyme (Fig. 5), it appears that the transition inter-
mediate formed by the Glu-155 enzymes is likely to be a
dimer (33, 34). However it is not clear whether this is the case
for wild type and A140D enzymes.
The population of the transition intermediate appears to
differ significantly between the Glu-155 containing and Glu-
155 enzymes. Based on the three-state model, the fractions of
the transitional intermediate and the native and unfolded
states at different urea concentrations were calculated and
plotted (Fig. 4, d–f). The population of intermediate formed
by the wild type and A140D enzymes is largely overlapped by
the unfolded fraction, suggesting that this intermediate is very
transitory and may indicate why there is no obvious interme-
diate state reflected in the equilibrium unfolding curves. In
contrast, the intermediate of the Glu-155 enzymes is clearly
distinguishable at lower urea concentrations and has an in-
creased area of exposed hydrophobic surface as illustrated by
the ANS binding data (Fig. 4c).
Thermodynamic Analysis of Urea-induced Unfolding—The
thermodynamic parameters for the Glu-155 containing and
Glu-155 deletion enzymes are shown in Table 3. The three-
state fit of tryptophan fluorescence data from the wild type
and A140D enzymes provided a similar total free energy
change of 14.4 and 14.3 kcal/mol, respectively, which is larger
FIGURE 5. The protein concentration dependence of equilibrium un-
folding of GSTO1-1 variants in urea. The unfilled symbols represent deter-
minations at 1 M protein, and the filled symbols represent determinations
at 8 M protein. The circles in panel A represent the wild type enzyme, and
the triangles in panel B represent the Glu-155/Glu-208 variant.
TABLE 3
Thermodynamic parameters characterizing the urea-induced unfolding transition monitored by tryptophan fluorescence and ANS binding
The data were fitted to a three-state transition model via a dimeric intermediate.
GN3 I0 mN3 I [Urea]1/2,1 GI3U0 mI3U [Urea]1/2,2 GN3U0
kcal/mol kcal/mol/M M kcal/mol kcal/mol/M M kcal/mol
Tryptophan fluorescence
WT 8.51  0.46 1.81  0.11 4.69  0.06 5.91  2.42 1.00  0.36 5.91  0.33 14.42
A140D 9.16  0.82 2.02  0.20 4.55  0.09 5.14  1.67 0.87  0.26 5.94  0.22 14.3
Glu-155/Glu-208 2.84  0.79 1.48  0.37 1.92  0.12 5.78  0.35 1.37  0.08 4.22  0.03 8.62
Glu-155/Lys-208 3.34  0.97 1.80  0.49 1.86  0.11 5.39  0.31 1.29  0.07 4.19  0.03 8.73
ANS binding
WT 7.65  2.43 2.45  0.80 3.11  0.11 7.07  0.42 1.44  0.08 4.91  0.03 14.72
A140D 5.43  2.41 2.10  0.91 2.58  0.14 5.58  0.57 1.13  0.12 4.93  0.06 11.01
Glu-155/Glu-208 3.51  1.55 1.95  0.77 1.77  0.17 6.54  0.58 1.55  0.13 4.20  0.04 10.05
Glu-155/Lys-208 3.89  1.64 1.88  0.79 2.06  0.15 4.98  0.62 1.27  0.14 3.92  0.07 8.87
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than that obtained for the Glu-155 enzymes (8.6 and 8.7
kcal/mol for Glu-155/Glu-208 and Glu-155/Lys-208, re-
spectively). Similar results were obtained from the ANS bind-
ing data. The main difference between the wild type and the
Glu-155 variant occurs in the initial unfolding to the transi-
tion intermediate. Studies using intrinsic fluorescence re-
vealed a free energy change for this first transition of around
8.5 kcal/mol for the wild type compared with around 2.8 kcal/
mol for the Glu-155 variant. These data suggest that the
enzymes with the Glu-155 deletion are less stable than Glu-
155-containing enzymes, and the lower stability of Glu-155
enzymes comes primarily from a propensity to enter the first
transition phase.
Reversibility of Unfolding—The ability of the enzymes to
re-fold after urea-induced unfolding was evaluated by fluores-
cence recovery and the restoration of catalytic activity (Fig. 6).
The two methods used here to monitor the refolding gave
similar results. Refolding of the wild type Glu-155-containing
enzymes was essentially complete after 1 h with the recovery
of around 95%. In contrast, the enzymes with the Glu-155
deletion regained only around 70% of their original activity or
fluorescence intensity over this period.
To identify whether the lower recovery of Glu-155 deletion
enzyme came from a lower refolding rate, an exponential re-
gression analysis was applied to the fluorescence recovery
data. For the wild type and A140D enzymes, a two-phase ex-
ponential regression was better than a single-phase exponen-
tial regression as improvements in the fit were observed in R2
(0.9984 and 0.9992 compared with 0.9924 and 0.9900, respec-
tively) in the S.E. of estimates (0.0050 and 0.0069 compared
with 0.0135 and 0.0158, respectively) and in the residual sums
of squares (0.0005 and 0.0002 compared with 0.0022 and
0.0030, respectively). Interestingly the refolding data for the
Glu-155/Lys-208 variant could be fitted to a single phase or
two-phase exponential regression with the same R2 (0.9978)
and residual sums of squares (0.0003) and a similar S.E.
(0.0053 and 0.0058, respectively). However the two-phase ex-
ponential regression generated an unusually high k1 of over
2200 min1 and other unusual parameters, suggesting that a
single phase exponential analysis is more appropriate for the
Glu-155/Lys-208 variant.
Therefore, the refolding curve of wild type and A140D en-
zymes monitored by fluorescence was better fitted by a two-
phase exponential equation, which respectively gave 3.18 
0.57 and 3.34  0.52 min1 for k1 and 0.22  0.06 min1and
0.27  0.05 min1 for k2, whereas the refolding of Glu-155/
Lys-208 variant followed single-phase exponential kinetics
with a rate of 4.04  0.80 min1. This suggests that the Glu-
155 variants still have a similar fast-refolding phase like the
wild type and A140D enzymes but have lost the second slow
refolding phase as shown in Fig. 6.
DISCUSSION
Previous studies have indicated that the polymorphic dele-
tion of Glu-155 causes a deficiency of GSTO1-1 in cell lines,
but the mechanism causing this deficiency is not clear. As the
deletion can potentially alter splicing at the end of exon 4, we
previously undertook Northern blotting analysis to eliminate
a splicing defect as a cause of the GSTO1-1 deficiency (20).
That study showed that T47D breast cancer cells that are
hemizygous for the Glu-155 deletion allele produce mRNA of
the appropriate size, suggesting that abnormal splicing is un-
likely to be the cause of the deficiency. Previous pulse-chase
studies in T47D cells indicate that the Glu-155 deletion pro-
tein has a shorter than normal t1⁄2 (20). Although this variant
can be expressed as an active enzyme in E. coli, the recombi-
nant enzyme is relatively heat-sensitive (20). Given the clini-
cal interest in GSTO1-1, we were interested in determining
the mechanism by which the Glu-155 deletion mediates this
deficiency.
The crystal structure indicated that the deletion of Glu-155
caused only small perturbations of the overall protein fold.
Although there is a slight decrease in the volume and appar-
ent accessibility of the H site, the distinct structural forms of
Glu-155 dimers observed in the crystal structures point to-
ward increased flexibility of the protein. This may explain the
previously observed increase in catalytic activity of Glu-155
mutants (Table 4), as conformations suitable for binding and
FIGURE 6. Refolding of GSTO1 variants. Symbols and solid curves represent
the recovery of fluorescence. The right-hand columns show the recovery of
activity with 4-nitrophenacylglutathione as a substrate (mean  S.D.).
TABLE 4
The activity of recombinant wild type and Glu-155 GSTO1-1 variants with a range of substrates
All activities are shown as mol/min/mg, mean  S.D. CDNB, 1-chloro-2,4,dinitrobenzene; 2,4-DCPG; S-(2,4-dichlorophenacylglutathione). All data were compiled
from Refs. 2, 8, and 19.
Enzyme CDNB Thiol transferase Dehydroascorbate Monomethyl arsonate Dimethyl arsonate 2,4-DCPG
Human GSTO1-1 0.047  0.01 2  0.21 0.13  0.005 0.33  0.037 0.12  0.006 1.3  0.1
0.039  0.01 2.6  0.26
Glu-155, Glu-208 6  0.09 0.25  0.045 0.65  0.007 0.3  0.014 1.3  0.05
Glu-155, Lys-208 0.063  0.01 4.8  0.07 0.21  0.03 0.67  0.066 0.37  0.015 1.1  0.03
3.6  0.36
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catalysis of diverse substrates are more accessible to the flexi-
ble mutant protein. The catalytic activity of the recombinant
Glu-155 enzymes and the absence of immunologically de-
tectable GSTO1-1 in T47D cells suggest that the deletion may
cause a defect in stability or folding rather than a loss of func-
tion. We found several structural factors that could have a
deleterious impact on stability including the increase in the
water accessible surface area, a reduction in buried hydropho-
bic surface area, and the large decrease in molecular contacts
between helices 5 and 7. Even the increased buried area of
dimer interface was not a positive factor because of the con-
comitant increase in the surface area of solvent-exposed hy-
drophobic residues.
The lower free energy change GN3U0 supports the lower
stability of the Glu-155 enzymes. We also found evidence
that at low urea concentrations the Glu-155 enzymes form a
transitional intermediate that is not significantly populated
by the Glu-155-containing enzymes. Because their first transi-
tion is not dependent on the protein concentration, the un-
folding intermediate formed by the Glu-155 enzymes ap-
pears to be a dimer with more hydrophobic area exposure
revealed by the ANS binding data. The nature of the interme-
diate formed by the Glu-155-containing enzymes is difficult
to identify with the present data.
The capacity of the Glu-155 deletion variants to refold after
complete unfolding in urea was limited compared with the Glu-
155 containing Ala-140 and Asp-140 enzymes (Fig. 6). This limi-
tation only occurred during the second slow phase of refolding.
Because refolding is usually thought to be the reverse of unfold-
ing, the refolding of the Glu-155 deletion enzymes is probably
limited by the population of the transitional intermediate. As
mentioned above, the intermediate has a larger exposed hydro-
phobic surface, which probably promotes precipitation or pre-
vents further refolding of the protein resulting in the lack of the
second slow phase for the Glu-155 enzymes. Intracellular pro-
teins are dynamic andmay be subjected to conformational
changes under different intracellular conditions. It is possible
that the increased accessibility to solvent and decreased contacts
in the Glu-155 deletion enzymemay promote unfolding and
restrict refolding by presenting a barrier of increased hydropho-
bic surface exposure, leading to a dynamic equilibrium that fa-
vors an unfolded state in vivo.
We, therefore, conclude that the deletion of Glu-155 causes
GSTO1-1 deficiency by its low stability, resulting from its in-
creased propensity to unfold, and a novel mechanism that inhib-
its refolding. The structural characteristics of the deletionmu-
tant, including a high accessible surface area and less buried
hydrophobic area as well as altered packing around Glu-155
agree with these observations. The results help us to understand
the impact of the Glu-155 deletion allele on the level of
GSTO1-1 activity in vivo, whichmay contribute to the observed
association of GSTO1-1 with the age at onset of Alzheimer dis-
ease and the activation of the pro-inflammatory cytokine IL-1.
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